These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11033836)

  • 1. Clinical efficacy of rhIL-11.
    Reynolds CH
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):32-40. PubMed ID: 11033836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor).
    Kaye JA
    Stem Cells; 1996; 14 Suppl 1():256-60. PubMed ID: 11012229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin.
    Isaacs C; Robert NJ; Bailey FA; Schuster MW; Overmoyer B; Graham M; Cai B; Beach KJ; Loewy JW; Kaye JA
    J Clin Oncol; 1997 Nov; 15(11):3368-77. PubMed ID: 9363868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and side-effect profile of rhIL-11.
    Smith JW
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):41-7. PubMed ID: 11033837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose reductions and delays: limitations of myelosuppressive chemotherapy.
    Cairo MS
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):21-31. PubMed ID: 11033835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
    Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and safety of rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia].
    Li L; Xu CG; Wang XW; Guo QS; Sun YH; Sun LM
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):377-9. PubMed ID: 16117904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
    Lei W; Liang J; Chen WG; Ma XZ; Xu M; Du LL
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):542-4. PubMed ID: 17147124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia.
    Kurzrock R
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):9-11. PubMed ID: 11033833
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of rhIL-11 on normal dogs and after sublethal radiation.
    Nash RA; Seidel K; Storb R; Slichter S; Schuening FG; Appelbaum FR; Becker AB; Bolles L; Deeg HJ; Graham T
    Exp Hematol; 1995 May; 23(5):389-96. PubMed ID: 7720811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy.
    Cantor SB; Elting LS; Hudson DV; Rubenstein EB
    Cancer; 2003 Jun; 97(12):3099-106. PubMed ID: 12784347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates.
    Zeidler C; Kanz L; Hurkuck F; Rittmann KL; Wildfang I; Kadoya T; Mikayama T; Souza L; Welte K
    Blood; 1992 Dec; 80(11):2740-5. PubMed ID: 1280477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.
    Tepler I; Elias L; Smith JW; Hussein M; Rosen G; Chang AY; Moore JO; Gordon MS; Kuca B; Beach KJ; Loewy JW; Garnick MB; Kaye JA
    Blood; 1996 May; 87(9):3607-14. PubMed ID: 8611684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    de Wit R; Verweij J; Bontenbal M; Kruit WH; Seynaeve C; Schmitz PI; Stoter G
    J Natl Cancer Inst; 1996 Oct; 88(19):1393-8. PubMed ID: 8827017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].
    Sun XF; Guan ZZ; Huang H; Zhou QH; Yi C; Zhang LJ; Zhu J; Li R; Zhou J; Zhang M; Guo Y
    Ai Zheng; 2002 Aug; 21(8):892-5. PubMed ID: 12478901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacologic basis for clinical use of rhIL-11 as an effective platelet-support agent.
    Berl T; Schwertschlag U
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):12-20. PubMed ID: 11033834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
    Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
    Kushner BH; Heller G; Kramer K; Cheung NK
    Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.